Efficacy of D-cycloserine augmented brief intensive cognitive-behavioural therapy for paediatric obsessive-compulsive disorder: A randomised clinical trial

Simple item page
dc.contributor.authorFarrell, Lara J.en
dc.contributor.authorWaters, Allison M.en
dc.contributor.authorTiralongo, Evelinen
dc.contributor.authorMathieu, Sharnaen
dc.contributor.authorMcKenzie, Matthewen
dc.contributor.authorGarbharran, Vinayen
dc.contributor.authorWare, Robert S.en
dc.contributor.authorZimmer-Gembeck, Melanie J.en
dc.contributor.authorMcConnell, Harryen
dc.contributor.authorLavell, Cassieen
dc.contributor.authorCadman, Jacindaen
dc.contributor.authorOllendick, Thomas H.en
dc.contributor.authorHudson, Jennifer L.en
dc.contributor.authorRapee, Ronald M.en
dc.contributor.authorMcDermott, Bretten
dc.contributor.authorGeller, Danielen
dc.contributor.authorStorch, Eric A.en
dc.date.accessioned2022-08-04T14:38:39Zen
dc.date.available2022-08-04T14:38:39Zen
dc.date.issued2022-01en
dc.description.abstractObjective To examine the efficacy of weight-adjusted D-cycloserine (DCS) (35 or 70 mg) relative to placebo augmentation of intensive exposure therapy for youth with obsessive-compulsive disorder (OCD) in a double-blind, randomised controlled trial, and examine whether antidepressant medication or patient age moderated outcomes. Methods Youth (n = 100, 7-17 years) with OCD were randomised in a 1:1 ratio to either DCS + exposure (n = 49) or placebo + exposure (n = 51). Assessments occurred posttreatment, 1 month later, and at 3 and 6 months. Pills were ingested immediately before sessions. Results Significant improvements on all outcomes were observed at posttreatment, and to 6-month follow-up. Treatment arms did not differ across time, with no significant time-by-medication interactions on symptom severity (T1 to T2 estimate: 9.3, 95% confidence interval [CI]: -11.2 to -7.4, and estimate -10.7, 95% CI: -12.6 to -8.7), diagnostic severity (T1 to T2 estimate: -2.0, 95% CI: -2.4 to -1.5 and estimate -2.5, 95% CI: -3.0 to -2.0) or global functioning (T1 to T2 estimate: 13.8, 95% CI: 10.6 to 17.0, and estimate 16.6, 95% CI: 13.2 to 19.9). Neither antidepressants at baseline nor age moderated primary outcomes. There were significantly fewer responders/remitters at 1- and 6-month follow-up among youth in the DCS condition stabilised on SSRIs, relative to youth not taking SSRIs. Conclusions DCS augmented intensive exposure therapy did not result in overall additional benefits relative to placebo. Intensive exposure proved effective in reducing symptoms for the overall sample.en
dc.description.notesNational Health and Medical Research Council, Grant/Award Number: APP1058025en
dc.description.sponsorshipNational Health and Medical Research Council [APP1058025]en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1002/da.23242en
dc.identifier.eissn1520-6394en
dc.identifier.issn1091-4269en
dc.identifier.pmid35084071en
dc.identifier.urihttp://hdl.handle.net/10919/111449en
dc.language.isoenen
dc.publisherWileyen
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectcognitive-behaviour therapyen
dc.subjectD-cycloserineen
dc.subjectexposure therapyen
dc.subjectOCDen
dc.titleEfficacy of D-cycloserine augmented brief intensive cognitive-behavioural therapy for paediatric obsessive-compulsive disorder: A randomised clinical trialen
dc.title.serialDepression and Anxietyen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
FarrellEfficacy2022.pdf
Size:
670.64 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Scholarly Works, Psychology
Destination Area: Adaptive Brain and Behavior (ABB)